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Lung cancer is the most common cause of cancer-related deaths that frequently
metastasizes prior to disease diagnosis. Circulating tumor cells (CTCs) are found in many
different types of epithelial tumors and are of great clinical interest in terms of prognosis
and therapy intervention. Here, we present and discuss epithelial cell adhesion molecule-
dependent and -independent capture of CTCs in non-small cell lung cancer (NSCLC) and
the clinical relevance of CTC detection and characterization. Taking blood samples and
analyzing CTCs as “liquid biopsy” might be a far less invasive diagnostic strategy than
biopsies of lung tumors or metastases. Moreover, sequential blood sampling allows to
study the dynamic changes of tumor cells during therapy, in particular the development
of resistant tumor cell clones.
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Introduction
Lung cancer is one of the most frequent and deadly diseases (1). Current therapeutic strategies in
particular for non-small cell lung cancer (NSCLC) are chemotherapy and drugs targeting specific
molecular targets and pathways (2). The number of specific targets is increasing and about a third of
NSCLC especially adenocarcinomas have specific targets, such as EGFR or ALK-rearrangements.
Since these therapeutic targets are only expressed in a subset of tumors or their expression is
heterogeneous within the tumor, the development of companion diagnostics that can be used for
stratification and/or monitoring of targeted therapies in individual patients is of utmost importance
for future drug development (2). Their development, however, is hampered by limited availability
of tumor tissue due to biopsy-associated risks to the patient and the limited representation of
tumor heterogeneity. Furthermore, longitudinal sampling under treatment to monitor developing
resistance toward the treatment is generally not an option if invasive biopsies are required.
Circulating tumor cells (CTCs)may become new biomarkers to fill this diagnostic gap. A sensitive
isolation method for CTCs holds great promise for early detection of minimal residual disease (3).
Furthermore, CTCs are discussed to be deployable as predictive biomarkers guiding individual
cancer treatment strategies (personalized medicine) (4). Hence, sensitive isolation and profound
molecular characterization of CTCs could serve as a “liquid biopsy” and help to improve individual
treatment regimens for cancer patients (5). So far, several reports have shown that CTC counts are
much higher in small cell lung cancer (SCLC) compared to those of NSCLC (4).
Here, wewill discuss the current state of research onCTCs inNSCLCpatients and point out future
directions to implement “liquid biopsies” based on the molecular and functional characterization of
CTCs into clinical practice.
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CTCs as Liquid Biomarker
Today, a large number of publications exist investigating the
potential clinical use of CTCs as a so-called liquid biomarker.
So far, strong evidence for CTCs as prognostic markers has
been collected for different types of epithelial tumors, including,
breast, prostate, and colorectal cancer (3). In addition, molecular
characterization of CTCs could be used to identify therapeu-
tic targets in inoperable patients or metastatic settings, when
patients cannot be re-biopsied. In some cases, the CTC count
may even be superior to that of conventional imaging methods
for response monitoring (6). Moreover, sequential CTC enu-
meration can also provide clinically relevant information on the
effectiveness and progression of a systemic treatment. There-
fore, CTCs are used as biomarkers in several ongoing clinical
trials (3, 7, 8).
Numerous (>50) different methods for CTC detection have
been published, with highly variable detection rates, sensitivity,
and specificity. Clearly two major technical hurdles have to be
tackled when trying to establish a CTC detection system. First, the
enrichment of single CTCs among millions of normal blood cells
(leukocytes, erythrocytes, and platelets); and second, the detection
of CTCs in the enriched cell fractions (3, 8).
Usually, CTC assays start with an enrichment step that opti-
mally depletes most of blood cells to allow an easier detection
of single CTCs or CTC clusters. The most commonly described
enrichment methods can be divided into label-dependent and
-independent methods. In the label-dependent positive selec-
tion methods, CTCs are enriched using protein markers that are
expressed by CTCs but not by the surrounding blood cells. The
cell surface protein epithelial cell adhesion molecule (EpCAM),
which is frequently used as capture antigen, is bound either to
magnetic devices, such as beads, or to some solid surface used
as CTC baits. Among the EpCAM-based enrichment strategies,
the semi-automated CellSearch® system is the most commonly
used technique, which is currently the only system that has been
cleared by the U.S Food and Drug administration (FDA). For
negative selection, CTCs are enriched by depleting leukocytes,
usually using a CD45-antibody alone or together with antibodies
against other antigens expressed on blood cells. Using this system,
viable CTCs have been enriched and subsequently cultured, giving
rise to stable CTC cell lines and/or injected into mice giving rise
to tumors in mice (9–12). Several different label-free enrichment
techniques have been published. These methods rely on some
physical properties of the CTCs, such as size, density, shape, or
rigidity (3, 8).
Even after a very efficient enrichment, usually several hundreds
or thousands of normal blood cells (lymphocytes, endothelial
cells, hematopoietic, and mesenchymal stem cells) still remain
and, thus, a sensitive and specific detection system is needed.
Optimally, a CTC marker should be expressed on all CTCs, but
not on any type of cells found in the blood. Clearly no single
marker exists that could be ubiquitously used even for specific
tumor entities due to the great heterogeneity found between and
within single tumors. For detection, usually molecular, immuno-
cytological or functional-based methods, and assays are used.
The molecular methods rely on either the detection of tumor-
specific mRNA expression (detected by RT-PCR) or specific
gene alterations (including e.g., sequencing, different types of
mutation-specific PCRs or FISH) (3, 8).
The most commonly used CTC detection methodologies rely
on the immunocytological fluorescence detection of tumor-
associated protein markers using different cocktails of antibodies.
These protein-based technologies are usually utilizing antibod-
ies that detect epithelial markers such as different members of
the keratin family, normally not expressed at detectable levels
in hematopoietic cells. DNA and RNA-based technologies can
be used in addition to the immunocytological detection of sin-
gle CTCs for verification and molecular characterization of the
CTCs. The rapid advances in both next-generation sequencing
and whole-genome amplification of single cells now allow the
detailed characterization of the genome or expressional land-
scape of individual cells (10–14). Functional assays such as the
EPISPOT technology detects secreted proteins from CTCs (e.g.,
prostate-specific antigen or cytokeratin-19) that can be cap-
tured by specific antibodies attached to the bottom of culture
dishes (3, 8).
In summary, CTCs represent a reliable prognostic factor in
breast, colon, and prostate cancer patients and, e.g., the detection
of CTCs by the FDA-approved CellSearch® system is increas-
ingly incorporated as a diagnostic tool to the clinics. Nonethe-
less, concerning NSCLC, the scientific community faces a greater
challenge for both the detection and the interpretation of CTCs.
Importantly,Wang et al. published recently ameta-analysis, where
they included theCTC results from1576NSCLCpatients reported
in 20 publications using different CTC detection methods. This
meta-analysis showed that the presence of CTCs is significantly
associated with a decreased disease-free and overall survival of
NSCLC patients, indicating that also in NSCLC CTCs could be
used as a diagnostic tool in the clinics (15).
CTC Detection by EpCAM-Based Methods
in Lung Cancer Patients
Despite the highly aggressive nature of NSCLC, it is known that
CTCs are less frequently observed in NSCLC patients compared
to e.g., prostate, breast, and ovarian cancer patients when detected
by EpCAM-based methods (16). Interestingly, in SCLC, EpCAM-
based methods detect CTCs in most patients. Indeed, both the
frequency of detected CTCs and the number of CTCs per SCLC
patient are among the highest reported compared to other tumor
entities (17).
Hou et al. performed CellSearch® CTC analysis on patient
cohorts consisting of both NSCLC and SCLC. At the time of
first diagnosis, 85% of SCLC (n= 97) patients were CTC positive.
The median number of CTCs among SCLC patients was 24 per
patient (range 0–44.896 CTCs/7.5ml of blood) (25). By contrast,
the same group showed that only 21% of 101 advanced NSCLC
patients were positive for CTCs (range 0–146) (see Table 1) (18).
CTCs were mainly detected in stage IV patients (32% positivity),
whereas stage IIIA patients were CTC negative. The low CTC
detection rate in NSCLC patients was also described by other
groups when using the CellSearch® system. CTC positivity rates
were recorded between 21 and 39% (19–22, 26). Beyond that,
Marchetti et al. could detect CTCs in 41% of NSCLC patients
Frontiers in Oncology | www.frontiersin.org September 2015 | Volume 5 | Article 2072
Hanssen et al. CTCs in lung cancer
TABLE 1 | CTC detection in patients with NSCLC using EpCAM-dependent
assays.
Group (reference) Patient disease
stage
Size of
cohort
Positivity
rate (%)
Krebs et al. (18) III–IV 101 21
Hofman et al. (19) I–IV 210 39
Tanaka et al. (20) I–IV 152 31
Isobe et al. (21) IV 24 33
Hirose et al. (22) IV 33 36
Marchetti et al. (23) EGFR mutation 37 41
Devriese et al. (24) IIIB–IV 46 30
harboring activating EGFR mutations (23). Devriese et al. iso-
lated and detected CTCs using EpCAM-targeted magnetic beads
followed by quantitative real-time PCR detecting expression of
CK7 and CK19. In line with the CellSearch® results, 30% of the
advanced NSCLC patients showed positive expression for the
marker CK7 and 9% were positive for CK19 (24).
In conclusion, fewer CTCs can be detected in NSCLC patients
especially in localized disease using EpCAM-based detection
methods compared to other cancer types. However, between 25
and 50% of these early stage patients with resectable tumors
develop metastatic relapse. Therefore, it is likely that CTCs in
NSCLC are missed with current EpCAM-based technologies.
EpCAM-Independent Detection of CTCs in
Lung Cancer
Several different EpCAM-independent isolation techniques were
applied for NSCLC by different groups (see Table 2). Krebs et al.
used a size-based isolation technique (ISET) and reported a pos-
itive CTC status in 32 out of 40 stage III–IV patients, whereas
CellSearch® detected CTCs in the same cohort only in 9 out
of 40 patients. Both methods add up to a CTC positivity rate
of 85% (27). Another study that used the ISET device was per-
formed by Hofman et al., detecting five times the CTC number
compared to CellSearch®, with CTC positivity rates of 50 ver-
sus 21% (19). Furthermore, Hou et al. reported that circulating
tumor microemboli (CTM), i.e., clusters of CTCs, were only
detected with the ISET filtration device in NSCLC but not with
CellSearch®, indicating a possible loss of EpCAM expression in
CTC clusters in NSCLC (25). Interestingly, CTC clusters can be
detected with the CellSearch® system in SCLC (25). Hosokawa
et al. reported another size-based isolation [miniaturized micro-
cavity array (MCA)] of CTCs and subsequent detection by CK
expression. They revealed a 77% CTC detection rate with a
median CTC number of 13 CTCs/7.5ml of blood (28). Another
EpCAM-independent study was performed by Dorsey et al. (29).
When using a telomerase-based assay for CTC detection, they
revealed that 65% of the stage III patient cohort was CTC pos-
itive. This publication included a pilot study that was further-
more showing a relation between CTC burden and treatment
success (29).
Negative depletion approaches were used by Nel et al., and
cells were subsequently stained for the epithelial markers CK and
EpCAM, the mesenchymal marker N-Cadherin, and the stem cell
marker CD133 in 43 NSCLC patients (31). The authors identified
TABLE 2 |CTC detection in patients with NSCLC using EpCAM-independent
assays.
Group (reference) Isolation device Patient
disease stage
Size of
cohort
Positivity
rate (%)
Hofman et al. (19) ISET I–IV 210 50
Krebs et al. (27) ISET III–IV 40 80
Pailler et al. (30) ISET IV 32 100
Hosokawa et al. (28) MCA IV 22 77
Nel et al. (31) Negative depletion II–IV 43 CK: 100
Dorsey et al. (29) Telomerase-based III 30 65
ISET, isolation by size of epithelial tumor cell; MCA, minituarized microcavity array.
a variety of different CTC subpopulations and stated that the
presence of mesenchymal CTCs (positive for N-Cadherin) and an
increased ratio of stem cell-like (positive for CD133) to epithe-
lial CTCs (positive for CK) is associated with poor treatment
response. Similarly, when Pailler et al. analyzed ALK-rearranged
CTCs, they observed a more mesenchymal phenotype with pos-
itivity for Vimentin and N-Cadherin but without CK expression
(30). The analysis of the matched primary tumors revealed a
prominent epithelial phenotype with a range from moderate to
strong CK and E-Cadherin expression in the tumor tissue. At
moderate expression of the epithelial markers, a significant mes-
enchymal marker expression was also observed. Upon application
of ALK inhibitors, the number of ALK-positive CTCs decreased,
suggesting that CTCs could serve for monitoring of ALK-targeted
therapy in NSCLC (30).
These results underline the fact that NSCLC patients obviously
can harbor different CTC subpopulations, including EpCAM-
positive and EpCAM-negative cells. Further isolation attempts
and phenotypic characterizations have to be done in order to fully
understand the CTC composition and the clinical relevance of
each subpopulation.
Monitoring of Tumor-Specific Alterations in
CTCs can Predict Therapy Response when
Using Targeted Therapies in NSCLC
Detection and monitoring of cancer-specific rearrangements and
mutations on CTCs has also been reported lately in a few stud-
ies. In 2012, Ilie et al. demonstrated that the patients’ ALK sta-
tus can reliably be determined via FISH analysis of CTCs in
NSCLC patients. In a patient cohort of 87 cases, they detected five
tumor biopsies as ALK positive. All these patients had also ALK-
positive CTCs (32). Similar results were also obtained by Pailler
et al. who could identify ALK-positive CTCs in all patients with
ALK-positive primary tumor. However, in average 63% of CTCs
were ALK positive. They further studied the relation of ALK-
rearranged CTCs and targeted therapy intervention with crizo-
tinib. Serial analysis of five patients showed that the number of
ALK-rearranged CTCs decreases during crizotinib therapy (30).
The detection and clinical relevance of ROS1-rearrangement in
CTCs of NSCLC patients undergoing crizotinib therapy has also
been reported lately. In this study, it was shown that the amount of
ROS1-rearranged CTCs increased after 2weeks discontinuation
of crizotinib therapy, which was consistent with the CT scan of
the patients. Patients not responding to crizotinib did not show
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any change in the level of rearranged CTCs (33). In addition to
these studies, Maheswaran et al. serially analyzed four EGFR-
mutated primary NSCLC tumor patients for EGFR mutation
in CTCs. Treatment with gefitinib caused in general a decline
in the CTC counts. They analyzed different EGFR mutations
including the mutation T790M, conferring an acquired resis-
tance against gefitinib. The FUP blood sample revealed an
increase in the proportion of CTCs with the T790M mutation,
in line with the acquisition of drug resistance, and the presence
of mutation correlated with reduced progression-free survival
(34). These studies suggest that changes in the tumor genotype
during treatment response can be representatively monitored
in CTCs.
Conclusion
The literature indicates that CTCs in NSCLC might have fre-
quently lost or downregulated EpCAM expression, probably as
consequence of EMT. Still, EpCAM-positive CTCs have been
shown to be relevant for the clinical outcome (15, 18). However,
as they are barely detectable in earlier disease stages, a reliable
combination of non-EpCAM- and EpCAM-based CTC detection
methods needs to be established and validated in clinical studies.
In addition to enumeration and the gain of prognostic infor-
mation, the molecular characterization of CTCs with regard to
molecular alterations relevant for therapy is now feasible (10, 13,
30, 35). In NSCLC, various molecular targets each comprising
only a minor subset of patients have been identified. Thus, tar-
geted therapy needs to be adapted to the molecular characteristics
of the NSCLC cells in individual patients. Taking blood samples
and analyzing CTCs as “liquid biopsy” (36) might be a far less
invasive diagnostic strategy than biopsies of lung tumors ormetas-
tases. Moreover, sequential blood sampling allows to study the
dynamic changes of tumor cells during therapy, in particular the
development of resistant tumor cell clones. While information on
genomic changes in tumor cells can also be obtained from circu-
lating DNA fragments (34, 37, 38), the capture of CTCs allows a
more in-depth characterization including functional in vitro and
in vivo studies using cell culture and xenograft models (10–12).
These studies will largely extend our knowledge about the biology
of tumor cell dissemination in NSCLC with potential clinical
implications for an improved treatment.
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